Neurocrine Biosciences Announces Conference Call and Webcast of Second Quarter 2025 Financial Results

Rhea-AI Summary

Neurocrine Biosciences (NASDAQ: NBIX) has scheduled its second quarter 2025 financial results conference call and webcast for July 30, 2025, at 1:30 p.m. Pacific Time. The company will release its Q2 2025 financial results at 1:00 p.m. PT on the same day.

Neurocrine Biosciences is a neuroscience-focused biopharmaceutical company with FDA-approved treatments for multiple conditions including tardive dyskinesia, Huntington's disease chorea, congenital adrenal hyperplasia, endometriosis, and uterine fibroids. The company maintains a diverse pipeline with several compounds in mid to late-phase clinical development.

News Market Reaction

+1.06%

1 alert

+1.06% News Effect

On the day this news was published, NBIX gained 1.06%, reflecting a mild positive market reaction.

Data tracked by StockTitan Argus on the day of publication.

Conference Call and Webcast Scheduled for Wednesday, July 30

SAN DIEGO, July 9, 2025 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced today that it has scheduled its second quarter 2025 financial results conference call and webcast for 1:30 p.m. Pacific Time (4:30 p.m. Eastern Time) on July 30, 2025.

The schedule for the press release and conference call / webcast is as follows:

• Q2 2025 Press Release: July 30, 2025 at 1:00 p.m. PT / 4:00 p.m. ET
• Q2 2025 Conference Call: July 30, 2025 at 1:30 p.m. PT / 4:30 p.m. ET
• Domestic Dial-In Number: 800-225-9448
• International Dial-In Number: 203-518-9708
• Conference ID: NBIX

The webcast can also be accessed on Neurocrine Biosciences' website under Investors at www.neurocrine.com. A replay of the webcast will be available on the website approximately one hour after the conclusion of the event and will be archived for approximately one month.

About Neurocrine Biosciences
Neurocrine Biosciences is a leading neuroscience-focused, biopharmaceutical company with a simple purpose: to relieve suffering for people with great needs. We are dedicated to discovering and developing life-changing treatments for patients with under-addressed neurological, neuroendocrine and neuropsychiatric disorders. The company's diverse portfolio includes FDA-approved treatments for tardive dyskinesia, chorea associated with Huntington's disease, classic congenital adrenal hyperplasia, endometriosis* and uterine fibroids*, as well as a robust pipeline including multiple compounds in mid- to late-phase clinical development across our core therapeutic areas. For three decades, we have applied our unique insight into neuroscience and the interconnections between brain and body systems to treat complex conditions. We relentlessly pursue medicines to ease the burden of debilitating diseases and disorders, because you deserve brave science. For more information, visit neurocrine.com, and follow the company on LinkedIn, X and Facebook.
(*in collaboration with AbbVie)

NEUROCRINE, the NEUROCRINE BIOSCIENCES Logo, and YOU DESERVE BRAVE SCIENCE are registered trademarks of Neurocrine Biosciences, Inc.

View original content to download multimedia:https://www.prnewswire.com/news-releases/neurocrine-biosciences-announces-conference-call-and-webcast-of-second-quarter-2025-financial-results-302501556.html

SOURCE Neurocrine Biosciences, Inc.

FAQ

When is Neurocrine Biosciences (NBIX) Q2 2025 earnings call?

Neurocrine Biosciences will host its Q2 2025 earnings call on July 30, 2025, at 1:30 p.m. PT (4:30 p.m. ET). The financial results will be released 30 minutes before the call.

How can I access Neurocrine Biosciences Q2 2025 earnings call?

The earnings call can be accessed via phone (domestic: 800-225-9448, international: 203-518-9708, Conference ID: NBIX) or through a webcast on Neurocrine's website under the Investors section at www.neurocrine.com.

What treatments does Neurocrine Biosciences (NBIX) have FDA approval for?

Neurocrine has FDA-approved treatments for tardive dyskinesia, Huntington's disease chorea, classic congenital adrenal hyperplasia, endometriosis, and uterine fibroids (the latter two in collaboration with AbbVie).

How long will Neurocrine's Q2 2025 earnings webcast be available?

A replay of the webcast will be available on Neurocrine's website approximately one hour after the event and will remain archived for approximately one month.